We’ve heard a lot this year about the IPO boom for biotech companies. Even after a few high-profile blowups (Ariad, Sarepta), the public biotech stock indexes are still outperforming the Nasdaq Composite Index and S&P 500. Some biotechs have been acquired for megabucks (Onyx, ViroPharma). We’ve heard about another biotech bubble in the making.
{iframe}http://www.xconomy.com/national/2013/11/18/biotech-startup-class-2013-dont-worry-short-list/{/iframe}